The main obstacle to better antimicrobial resistance (AMR) management is not a technological deficit. Advanced diagnostics exist, but healthcare systems struggle to implement them. The key is generating real-world evidence and health economic data to convince policymakers and change clinical practice.

The ambitious goal of prescribing no antibiotics without a diagnostic by 2030 cannot be achieved by technology alone. It requires a systemic effort involving national action plans and policy reinforcement, driven by partnerships between public entities, private companies, academics, policymakers, and scientists.

Unlike military radar for missiles, the world has no passive, global alert system for emerging pathogens. We currently rely on a slow, reactive process where sick patients present symptoms at hospitals, significantly delaying detection and response, as was the case with COVID-19.

Unlike other resistant bacteria like MRSA which can be cleared from the body, CPE colonizes the gut and has no proven therapy for eradication. Patients can remain carriers for months or years. This critical difference makes rapid screening and transmission prevention the only effective long-term strategy.

An asymptomatic partner can repeatedly reinfect their symptomatic partner with parasites through shared household surfaces like toilets and bedsheets. This necessitates testing and treating all household members simultaneously, not just the individual showing symptoms.

Even for common conditions like pneumonia, current diagnostic methods like sputum and blood cultures fail to identify a bacterial cause in 60% of cases. This diagnostic gap leads to clinical guesswork, resulting in dangerous under-treatment. In one study, one in eight patients with a bacterial infection was sent home from the ER without antibiotics.

The field of infectious disease is moving away from empirical treatment toward its own version of precision medicine. Similar to how oncology uses companion diagnostics to guide therapy, new rapid molecular tests are enabling clinicians to identify the specific organism and its resistance profile to prescribe the right antibiotic at the right time.

Reducing diagnostic time for superbugs like CPE from 48 hours to under one hour is transformative. This speed allows clinicians to implement isolation measures *before* an asymptomatic patient spreads the bacteria through routine procedures like scans or operations, fundamentally shifting the paradigm from reaction to prevention.

Evolutionary modeling shows that taking antibiotics beyond symptom resolution can be counterproductive. It needlessly kills off susceptible bacteria, creating a perfect environment for resistant strains to flourish. The optimal strategy is often to stop once the immune system can handle the rest, contrary to decades of medical advice.